gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BTMDHealthcarePharmaceuticals

Biote Corp. Class A Common Stock (BTMD)

$1.23+9.82%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.23▼ 56.99% in range
Nov 4, 2025Low $1.03 · High $2.93Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Biote closed at $1.23 on Nov 4, up 9.82%, 58.0% below its 52-week closing high. Volume of 232.0K shares was 2.18× its 20-day average (well above normal).

Split-adjusted performance: +7.9% over one month, -44.1% over six months, -56.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $44.23M, down 9.5% from a year earlier, with a net margin of -14.8%.

Short interest was 1.2M shares at the Oct 15 settlement, up 9.0% from the prior report (5.4% of float, 7.5 days to cover).

Market cap$35.3M28.7M shares
Revenue · quarter$44.2M−9.5% YoY
Diluted EPS$-0.23−330.0% YoY
P/E · TTM6.0×P/S 0.2×
Net margin-14.8%Gross 65.4%
Dividend yieldNone
52-week range1.03 – 2.93−58.0% from high
Volume232.0K2.18× 20-day avg
Volatility · 60d69.6%Annualised
Short % of float5.4%7.5 days to cover
Net cash-$110.3MCash $11.2M
Next earnings—Not scheduled
Split-adjusted performance
1W +7.0%1M +7.9%3M −24.5%6M −44.1%YTD −52.7%1Y −56.5%3Y −76.5%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum30
Revenue growth32
Net margin60
Value (low P/E)81
Size27

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short1.2M+9.0% vs prior
Days to cover7.5Settled Oct 15
% of float5.4%
Short vol. 10d40.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BTMDBiote$1.23+9.82%−44.1%−9.5%−14.8%6.0$35.3M
NNVCNanoViricides$1.38−3.50%−5.5%———$35.2MCompare
IBOImpact BioMedical$4.10+1.99%−48.8%−57.1%−23300.0%44.4$35.0MCompare
VERUVeru$2.20+1.85%−0.9%———$37.5MCompare
LITSLite Strategy$1.08+3.85%−9.2%———$32.8MCompare
GRCEGrace Therapeutics$1.81−1.63%−23.6%———$38.1MCompare
SCYXSCYNEXIS$3.84−2.54%−51.1%−82.8%3147.7%—$38.2MCompare
RMTIRockwell Medical, Inc. (DE)$8.05−0.49%−0.6%+10.6%−7.5%—$32.4MCompare
ALDXAldeyra Therapeutics$0.6474+4.32%−62.8%———$39.1MCompare

News about Biote

All news →
biote Corp. (BTMD) Tops Q3 Earnings EstimatesZacks Investment Research · 12h ago▼ Negative

Quick answers

What does Biote do?
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
What is BTMD's market cap?
$35.27M, based on the Nov 4 close of $1.23.
What is BTMD's P/E ratio?
6.0× trailing-twelve-month earnings of $5.86M.
Does Biote pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BTMD is sold short?
1.2M shares, 5.4% of float, as of Oct 15, 2026.
What sector is BTMD in?
Healthcare, in the Pharmaceuticals industry.

About Biote

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.

HQ: Irving, TX223 employeesListed May 27, 2022biote.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology